Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-site, Open-label Study to Determine the Safety and Tolerability of Single and Multiple Doses of Intranasally Administered LMN-301 in Healthy Volunteers

NCT06030414 is registered in ClinicalTrials.gov with Lumen Bioscience, Inc. as lead sponsor.

NCT NCT06030414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06030414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-site, Open-label Study to Determine the Safety and Tolerability of Single and Multiple Doses of Intranasally Administered LMN-301 in Healthy Volunteers
Lead sponsor
Lumen Bioscience, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 6, 2023
Completion date
April 3, 2024
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19